Editas Medicine Inc (EDIT)

NASD · Healthcare · Biotechnology · USA

Editas Medicine Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Editas Medicine develops genomic medicines using CRISPR gene editing technology to treat serious diseases. The company employs a proprietary platform based on CRISPR/Cas9 and CRISPR/Cas12a systems to edit DNA sequences with precision. Its lead candidate targets hyperlipidemia through in vivo gene editing, while pursuing partnerships for cell therapy and out-licensing technology.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Editas Medicine Inc stock.

Our verdict on EDIT

Overvalued: intrinsic value $0.03 per share, market price $1.83, margin of safety -5958.7% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $1.83 is 5959% above that value.

ETFs with the most weight in EDIT

17 more funds hold it; the full list is part of the paid plan.

More on EDIT

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than EDIT in Biotechnology

126 more in this industry show a wider margin of safety.

Is EDIT undervalued or overvalued?

EDIT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.03; the price of $1.83 is 5959% above that value.

What is the intrinsic value of EDIT?

$0.03 per share (as of the 2026-11-17 close), against a market price of $1.83. That is a margin of safety of -5958.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.